VKTX vs. ITCI, JAZZ, CYTK, CERE, ELAN, IONS, ASND, APLS, LEGN, and BPMC
Should you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Intra-Cellular Therapies (ITCI), Jazz Pharmaceuticals (JAZZ), Cytokinetics (CYTK), Cerevel Therapeutics (CERE), Elanco Animal Health (ELAN), Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), Apellis Pharmaceuticals (APLS), Legend Biotech (LEGN), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.
Viking Therapeutics (NASDAQ:VKTX) and Intra-Cellular Therapies (NASDAQ:ITCI) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations, community ranking and media sentiment.
Viking Therapeutics has higher earnings, but lower revenue than Intra-Cellular Therapies. Viking Therapeutics is trading at a lower price-to-earnings ratio than Intra-Cellular Therapies, indicating that it is currently the more affordable of the two stocks.
Viking Therapeutics has a net margin of 0.00% compared to Intra-Cellular Therapies' net margin of -30.08%. Viking Therapeutics' return on equity of -18.41% beat Intra-Cellular Therapies' return on equity.
Viking Therapeutics received 94 more outperform votes than Intra-Cellular Therapies when rated by MarketBeat users. Likewise, 79.92% of users gave Viking Therapeutics an outperform vote while only 67.34% of users gave Intra-Cellular Therapies an outperform vote.
76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 4.7% of Viking Therapeutics shares are held by company insiders. Comparatively, 3.4% of Intra-Cellular Therapies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Viking Therapeutics had 14 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 32 mentions for Viking Therapeutics and 18 mentions for Intra-Cellular Therapies. Viking Therapeutics' average media sentiment score of 0.81 beat Intra-Cellular Therapies' score of 0.61 indicating that Viking Therapeutics is being referred to more favorably in the media.
Viking Therapeutics presently has a consensus target price of $112.25, indicating a potential upside of 48.83%. Intra-Cellular Therapies has a consensus target price of $90.17, indicating a potential upside of 24.71%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Viking Therapeutics is more favorable than Intra-Cellular Therapies.
Viking Therapeutics has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500.
Summary
Viking Therapeutics beats Intra-Cellular Therapies on 14 of the 17 factors compared between the two stocks.
Get Viking Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viking Therapeutics Competitors List
Related Companies and Tools
